ReviewInternational journal of molecular sciences2020
The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Association between disease activity, arterial stiffness, and 10-year cardiovascular risk in patients with rheumatoid arthritis: a cross-sectional study.Rheumatology international · 2026Article
- Triglycerides as a predictor of activity and severity in thyroid eye disease: a multicentre study.The British journal of ophthalmology · 2026Article
- Review
- Expression and clinical significance of fatty acid metabolism-related genes in PBMCs of SSc patients.Clinical rheumatology · 2026Article
- The SIRT1/STAT3 axis as a central regulator of immune, inflammatory, and lipid metabolic dysregulation in rheumatoid arthritis: therapeutic implications.Frontiers in immunology · 2026Review
- Lipoprotein (a) and inflammatory bowel disease: a systematic review and meta-analysis.Annals of gastroenterology · 2026Article
- AdaBoost-based differential diagnosis of gouty arthritis and rheumatoid arthritis: model construction, temporal validation, and SHAP visualization.Frontiers in medicine · 2026Article
- Atherosclerosis features in rheumatic diseases - focus on peripheral artery disease.Frontiers in immunology · 2026Review
- Mitochondria as a Disease-Relevant Organelle in Rheumatoid Arthritis: A Key Breakout in Fight Against the Disease.Biomedicines · 2025Review
- Metabolic and systemic inflammation status in rheumatoid arthritis-fasting blood glucose as a primary predictor of rheumatoid arthritis risk: a cross-sectional study in Iran.Osong public health and research perspectives · 2025Article
- Cardiovascular disease risk factors in newly diagnosed rheumatoid arthritis: A retrospective cohort study.American journal of preventive cardiology · 2025Article
- Assessments of CYP-Inhibition-Based Drug-Drug Interactions Between Tofacitinib and Lipid-Lowering Agents in Rats Both In Vitro and In Vivo.Pharmacology research & perspectives · 2025Article
- Development and validation of a prognostic nomogram for predicting mortality risk in adult rheumatoid arthritis: an analysis of NHANES 1999-2018 data.Frontiers in immunology · 2025Article
- The relationship between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and rheumatoid arthritis: a cross-sectional study.Frontiers in nutrition · 2025Article
- Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary.Rheumatology and therapy · 2024Article
- Cardio-rheumatology: the cardiovascular, pharmacological, and surgical risks associated with rheumatological diseases in women.Canadian journal of physiology and pharmacology · 2024Review
- High-density lipoprotein cholesterol subfraction HDL2 is associated with improved endothelial function in systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Identification and Verification of Novel Biomarkers Involving Rheumatoid Arthritis with Multimachine Learning Algorithms: An In Silicon and In Vivo Study.Mediators of inflammation · 2024Article
- Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis.Arthritis research & therapy · 2023Article
- Metabolic Syndrome and Rheumatoid Arthritis Activity: An Analysis of Clinical, Laboratory, and Ultrasound Parameters.Nutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the most common manifestations associated with rheumatoid arthritis (RA) are synovial damage and inflammation, the systemic effects of this autoimmune disorder are life-threatening, and are prevalent in 0.5-1% of the population, mainly associated with cardiovascular disorders (CVDs). Such effects have been instigated by an altered lipid profile in RA patients, which has been reported to correlate with CV risks. Altered lipid paradox is related to inflammatory burden in RA patients. The review highlights general lipid pathways (exogenous and endogenous), along with the changes in different forms of lipids and lipoproteins in RA conditions, which further contribute to elevated risks of CVDs like ischemic heart disease, atherosclerosis, myocardial infarction etc. The authors provide a deep insight on altered levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) in RA patients and their consequence on the cardiovascular health of the patient. This is followed by a detailed description of the impact of anti-rheumatoid therapy on the lipid profile in RA patients, comprising DMARDs, corticosteroids, anti-TNF agents, anti-IL-6 agents, JAK inhibitors and statins. Furthermore, this review elaborates on the prospects to be considered to optimize future investigation on management of RA and treatment therapies targeting altered lipid paradigms in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.